Periodic Reporting for period 1 - LipidDrive (LipidDrive - Lipidomics cloud computing platform and app)
Reporting period: 2017-09-01 to 2018-02-28
Lipidomics is an innovative diagnostic approach that studies quantifiable information about the profile and interaction of lipids, which are the most common biological molecule in humans. There are thousands of bioactive lipids that play key roles in all kinds of diseases. Mass spectrometry is enabling greater analysis of lipids to identify indicators of health and disease. However, its full potential is blocked by the lack of data standardization, processing capacity and collaboration. This resolution commences with the era of the EU based LipidDrive; the first-ever cloud computing online service accessible through web browsers.
Through phase 1 SME funding a successful feasibility study of the innovative LipidDrive product has been accomplished. It has been performed according to the proposed work tasks, fulfilling the targeted objectives and timelines. The results are comprehensive, where LipidDrive has undergone a meticulous technical development, of which much has been gratefully received from feedback of beta users, customer voice, and through other communications. The product has been majorly advanced, following the targeted goals of meeting the current and future customer and market needs. LipidDrive is protected and possessing the essential elements for a strategic market launch targeted in solving major business challenges for multiple target groups. Through an in-depth commercialization study a market attractive business plan has been assembled to be distributed to potential investors and serve as the groundwork for applying for an SME Phase 2 in the next coming months. Hence, the phase 1 funding has permitted preparing the launch of LipidDrive in new EU markets, scale up, and achieve profitability and sustainability.
LipidDrive revolutionizes the field by combining simplicity, unlimited power, control, accessibility, connectivity and user friendliness into a single solution. It focuses on data standardization and reference material matching, allowing lipidomics to enter regulatory environments for pharmaceutical studies, as well as clinical situations such as hospital diagnostics. Hence, it sets new cornerstones for the future that will transform lipidomics from a niche field into a mass market health service, possessing the elements and functions to become the gold standard in lipidomics by releasing the current handbrakes and triggering the awakening of its true potential in personal medicine and health diagnosis.